JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 450 participants.

Also called NCT05064540

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
  • Endologix Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05064540
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05064540. Randomized; no masking; primary purpose treatment. Start 2021-09-20 (actual); primary completion 2032-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Acronym
JAGUAR
Condition
AAA
Condition
AAA - Abdominal Aortic Aneurysm
Intervention (Device)
Alto Abdominal Stent Graft System
Intervention (Device)
FDA Approved EVAR AAA Graft Systems
Lead sponsor
Endologix (class: industry)

Record details

Record id
cardio:ct-nct05064540
Content hash
836c42c2f72761e357a2b911394f4350e1ec3908f4edeae6651c84be83c4b023